PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, May 05, 2025 Recursion Pharmaceuticals Reports Q1 Results and Strategy Update Recursion Pharmaceuticals reports Q1 EPS (50c), consensus (52c) PremiumThe FlyRecursion and HealthVerity announce agreement Largest borrow rate increases among liquid names Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today PremiumThe FlyRecursion announces first patient dosed in Phase 1 REC-3565 study Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals Recursion Pharmaceuticals call volume above normal and directionally bullish 
